Heartburn drug tested against pancreatic cancer in early trial
NCT ID NCT04930991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether high doses of omeprazole, a common heartburn medication, could safely change certain markers in pancreatic tumors. The trial planned to enroll 25 patients with exocrine pancreatic cancer who were scheduled for surgery. Participants took omeprazole for 12–14 days before their operation, and researchers looked at safety and changes in tumor biomarkers. The study was terminated, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- omeprazole (a common heartburn drug, given at high doses)
- What this could lead to
- If successful, this could point toward a way to make pancreatic cancer cells more vulnerable to treatment by altering the tumor environment.
- What could go wrong
- This was a very early (phase 0) study with only 25 patients, and it was terminated early, so results are limited. High-dose omeprazole may cause side effects or not affect the tumor at all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXOCRINE PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.